- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00858130
Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS) (VeinoPlus)
Optimal Intensity and Frequency of a Portable Electrical Muscle Stimulator (VeinoPlus) to Improve Symptoms of Postthrombotic Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to determine the optimal electrical stimulation intensity level at which subjects using the portable electrical muscle stimulator (VeinoPlus) have the largest benefit for relief of post thrombotic symptoms. To determine if the subjects reported benefit from the device and willingness to continue using the device.
Subjects will be pre-screened on the phone for eligibility, and an initial appointment will be set. The subject will be given a device and complete a quality of life survey. The subject will also be assessed on the Villalta scale. After two months, the subjects will return for the final visit where the Villalta scale and quality of life survey will be reassessed, and the device taken back.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill; University of North Carolina Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >18
- Presence of previously objectively documented unilateral, lower extremity deep venous thrombosis
- Presence of PTS (typical pain and swelling - worse after standing and vertical activity and relieved by rest and the horizontal position), severe enough that the patient is interested to explore a treatment option that might improve these symptoms. Symptoms had to have been stable for ≥ 3 months. Unstable symptoms are defined as: worsening, improving or variable symptoms over preceding months.
- Subjects must be willing and able to give written informed consent.
Exclusion Criteria:
- Inability or refusal to provide informed consent
- Pregnancy
- Women of child bearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period
- Geographic inaccessibility to prevent scheduled return evaluations
- Incapable of responding to questionnaires
- Expected lifespan <6 months
- Presence of cardiac pacemaker
- History of cardiac arrhythmia
- Presence of infected, or inflamed areas or skin eruptions; phlebitis, thrombophlebitis, active venous ulceration
- History of seizures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Veinoplus
Every subject enrolled in study will be in this experimental arm.
VeinoPlus device will be used by all enrolled subjects.
|
The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions.
The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes.
The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired.
Subjects will use the device however they see fit for 2 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Optimal Electrical Stimulation Intensity Level for Largest Benefit in Relief of Symptoms
Time Frame: Visit 2 (Week 8)
|
The VeinoPlus® electrically stimulates leg muscles via motor nerves, causing muscle contractions.
Two electrode pads are placed on the skin of the leg.
Pad positions can be chosen by the patient, such as (a) both pads on the calf muscle of one leg, (b) one pad on the calf muscle and one on the plantar aspect of the foot of one leg, and (c) a pad posteriorly on each calf.
Length of treatment is programmed into the device and is 20 minutes.
The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations during the treatment cycle if desired.
The intensity ranges from zero to fifty, with zero being no electrical stimulation, and fifty the highest intensity, which carries low quantities of electrical energy (<5 micro coulombs).
In this study subjects used the device at any setting, as many times a day as they liked, and varying the placement of the electrodes.
|
Visit 2 (Week 8)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Study Participants Classified as a "Clinical Success"
Time Frame: Visit 2 (Week 8)
|
Clinical success was defined by the patient reporting benefit (moderate improvement of symptoms after having used the device) and an interest and willingness to continue using the device.
For this study both legs were measured, but only the more severely affected leg (as determined by higher Villalta score) was used to determine clinical success.
Patients were asked the following question: "How much have symptoms improved?"
with the following possible responses: "a little;" "moderate;" "a good deal;" "a great deal;" or "a very great deal."
|
Visit 2 (Week 8)
|
Number of Study Participants With Improvements in PTS Severity (Villalta Score)
Time Frame: Visit 2 (Week 8)
|
The Villalta PTS scale is based on patient symptoms including cramps, pain, and redness and was used to characterize PTS severity.
Points are given for 11 descriptors according to severity from 0 (not present) to 3 (severe) with overall scores ranging from 0 to 33.
Higher scores represent more severe disease.
A score of ≥ 5 indicated mild PTS; 10-14 moderate PTS; and a score of ≥15, or the presence of a venous ulcer, indicated severe PTS.
Those participants with a Villalta score decrease at Visit 2 in comparison to Visit 1 were counted as having improved.
|
Visit 2 (Week 8)
|
Number of Study Participants With Improvements in QOL (VEINES-QOL Score)
Time Frame: Vist 2 (Week 8)
|
The VEINES-QOL/Sym is a patient-based questionnaire designed for self-completion and measures DVT impact on symptoms and QOL from patients' perspective.
It contains 26 items covering patient DVT: symptoms, limitations in daily activities, and psychological impact.
Two separate summary scores are produced ranging from 0 to 100; a disease-specific QOL (VEINES-QOL) and venous symptoms (VEINES-Sym).
For both the VEINES-QOL and VEINES-Sym, higher scores indicate a better QOL.
Instruments were completed at Visits 1 and 2 (Follow-up).
Those participants with a VEINES-QOL score increase at Visit 2 in comparison to Visit 1 were counted as having improved.
|
Vist 2 (Week 8)
|
Number of Study Participants With Improvements in Venous Symptoms (VEINES-Sym Score)
Time Frame: Vist 2 (Week 8)
|
The VEINES-QOL/Sym is a patient-based questionnaire designed for self-completion and measures DVT impact on symptoms and QOL from patients' perspective.
It contains 26 items covering patient DVT: symptoms, limitations in daily activities, and psychological impact.
Two separate summary scores are produced ranging from 0 to 100; a disease-specific QOL (VEINES-QOL) and venous symptoms (VEINES-Sym).
For both the VEINES-QOL and VEINES-Sym, higher scores indicate a better QOL.
Instruments were completed at Visits 1 and 2 (Follow-up).
Those participants with a VEINES-Sym score increase at Visit 2 in comparison to Visit 1 were counted as having improved.
|
Vist 2 (Week 8)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Stephan Moll, MD, UNC Chapel Hill, Department of Medicine, Division of Hematology/Oncology
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Skin Diseases
- Disease
- Gastrointestinal Diseases
- Leg Ulcer
- Skin Ulcer
- Embolism and Thrombosis
- Intestinal Diseases
- Malabsorption Syndromes
- Peripheral Vascular Diseases
- Phlebitis
- Varicose Veins
- Syndrome
- Thrombosis
- Venous Thrombosis
- Postthrombotic Syndrome
- Postphlebitic Syndrome
- Varicose Ulcer
- Venous Insufficiency
- Blind Loop Syndrome
Other Study ID Numbers
- 08-2143Veinoplus
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Deep Vein Thrombosis
-
University of OklahomaPfizerCompleted
-
University Medical Center GroningenCompletedSuspected Upper Extremity Deep Vein ThrombosisAustria, Netherlands, Italy, Belgium, Switzerland, Germany, United States
-
National Taiwan University HospitalUnknownUpper Extremity Deep Vein Thrombosis, SecondaryTaiwan
-
University of Missouri-ColumbiaTerminatedDEEP VEIN THROMBOSISUnited States
-
Vetex Medical Ltd.CompletedDeep Vein Thrombosis LegIreland, Germany, Bulgaria, United Kingdom
-
MinaPharm PharmaceuticalsRecruitingProphylaxis of Deep Vein ThrombosisEgypt
-
UPECLIN HC FM Botucatu UnespCompletedProphylaxis of Deep Vein ThrombosisBrazil
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)CompletedSuspected Deep Vein ThrombosisCanada
-
Diakron PharmaceuticalsCompleted
-
BayerRecruitingThrombolysis | Symptomatic Proximal Deep Vein ThrombosisBelgium, France, Italy, Netherlands, Canada, Germany, Czechia
Clinical Trials on VeinOPlus
-
University Hospital, AngersCompletedPeripheral Artery DiseaseFrance